ATH 33.3% 0.4¢ alterity therapeutics limited

What to hopefully look forward too, page-34

  1. 1,005 Posts.
    lightbulb Created with Sketch. 209
    Two things:
    1. Why wouldn't ATH re-enlist Ph2 participants (amongst new participants)for Ph3? Seems logical and would provide further valuable longer term data?
    2. If we are already talking about Ph3, this is encouraging as Ph2 must just be a formality?
    A patience game IMO from here on in.

 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.